For Immediate Release
Chicago, IL – May 10, 2019 – Zacks Value Trader is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:
What Is a Value Stock?
Welcome to Episode #140 of the Value Investor Podcast.
Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio, shares some of her top value investing tips and stock picks.
Before this year’s Berkshire Hathaway annual meeting in Omaha, Warren Buffett announced that one of his lieutenants that invests for the Berkshire portfolio, had bought shares of Amazon (AMZN - Free Report) in the first quarter.
We don’t yet know how large the position is. Buffett reassured shareholders that his team is still following the value investing strategy.
But are they?
Benjamin Graham’s Keys to Finding Value Stocks
Investors should know what makes up an actual “value” stock.
It isn’t simply a cheap growth stock.
There are certain fundamentals that should be there in value stocks including a low P/E, 5-years of earnings growth, and a low Price-to-Book ratio.
Screening for some of Graham’s requirements produced a list of 11 stocks.
3 Value Stocks That Pay Dividends
1. Citigroup (C - Free Report) is cheap with just a forward P/E of 9. It pays a nice dividend yielding 2.6%. It also has earnings growth, with a PEG ratio of 0.7.
2. CVS (CVS - Free Report) shares have sunk as investors have fled the healthcare stocks on worries about Medicare-for-all. CVS now owns Aetna, one of the largest health insurers. It’s also cheap, with a forward P/E of 8.1. It pays a dividend of 2%.
3. Lincoln National (LNC - Free Report) sells life insurance, handles employee benefits, and does wealth management. It has a forward P/E of just 7. Lincoln pays a dividend with a yield of 1.3%.
What else should you know about what makes a value stock?
Listen to this week’s podcast to find out.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.